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ABSTRACT Based on recent experimental evidences of the transmission of prion diseases due to a particular transmem-
brane form (termed CtmPrP), we propose a theoretical model for the molecular mechanism of such conformational diseases, in
which a misfolded CtmPrP induces a similar misfolding of another CtmPrP. Computer simulations are performed to investigate the
correlation between folding time and the concentration of misfolded PrP in various processes, including dimerization, trimer-
ization, and cooperative dimerization. By comparing with the experimental correlation curve between incubation time and
injected dose of scrapie prions, we conclude that cooperative dimerization may play an important role in the pathological
mechanism of prion diseases.
INTRODUCTION
Prion diseases, such as scrapie, bovine spongiform encepha-
lopathy, Creutzfeldt-Jakob disease, and Gerstmann-Straussler-
Scheinker disease, are fatal neurodegenerative disorders
characterized by dementia, ataxia, and cerebral spongiosis
(1–5). They constitute a heterogeneous group of infectious,
sporadic, and inheritable conditions, which are now believed
to be due to conformational conversion of a normal brain
prion protein called PrPc to a protease-resistant isoform
denoted PrPSc. Based on the correlation between the accu-
mulation of PrPSc and the degree of neuronal damage during
the course of prion diseases, it is often assumed that this
isoform is the main cause of neurodegeneration.
The role of PrPSc in the pathologic mechanism of prion
diseases is currently unknown. Recent experiments have
observed that PrPSc deposition fails to cause disease in brain
tissue lacking PrPc and that the time course of PrPSc depo-
sition in the brains of mice expressing low levels of PrPc
does not correlate with the time course of neurodegeneration
(6,7). Conversely, it is also observed that substantial neuro-
degeneration could occur in the absence of PrPSc accumu-
lation in several prion diseases (8–12). These observations
suggest that PrPSc is not directly toxic and its accumulation is
not the only cause of pathology in prion diseases.
Studies of PrP translocation at the endoplasmic reticulum
(ER) membrane have found three topologic forms of PrP,
including one cell-surface form (secPrP) and two transmem-
brane (TM) forms (CtmPrP and NtmPrP) (13–15). Several
pieces of evidence have implied the importance of CtmPrP in
the pathogenesis of prion diseases. It is found that transgenic
mice overexpressing CtmPrP develop a spontaneous neuro-
logical disease with scrapie-like features, in the absence of
PrPSc. In addition, patients affected by Gerstmann-Straussler-
Scheinker disease associated to an A117V mutation exhibit
an increased production of this TM form of PrP, suggesting
that the basis of this disease lies in increased production of
CtmPrP (16,17). These ﬁndings suggest that CtmPrP may have
important implications for a broad range of neurodegener-
ative diseases. Nevertheless, not much is known about the
pathological mechanism so far.
Numerous computational studies have provided valuable
information about the structure and mechanism of formation
of amyloids by using various modeling techniques and var-
ious levels of protein representation (18–22). Simulations at
the atomic resolution can study relative stability and ﬂexi-
bility of the native structure of prions, their amyloidlike
model structure, and possible intermediate structures during
aggregation (19,20). However, it would be computationally
too demanding to investigate protein refolding and aggrega-
tion. On the other hand, idealized simple lattice models have
shown that prion aggregation can lead to signiﬁcant change of
the single chain conformation (21). Moreover, simulations at
protein level can provide a bridge between the short distance
and timescales covered in individual protein models and the
long time, macroscopic realm of chemical kinetics (22).
In this work, we propose a model for the contact-induced
structure transformation of the transmembrane domain of
CtmPrP, which is studied by Monte Carlo simulations using a
coarse-grained protein model. In this model, the transmem-
brane domain can fold into a well-deﬁned helical ‘‘native
conformation’’ (Fig. 1 a) and also assume a metastable
b-type structure (Fig. 1 b). For a protein monomer, the
helical structure corresponds to the global energy minimum
and the metastable structure to a higher-energy local min-
imum of the energy landscape. For a system of more than
one chain, the ground state structure of the energy landscape
is a linear crystal consisting of b-form chains. Similar
mechanisms have been previously proposed for a prionlike
propagation in solution using a lattice model (23,24) or an
off-lattice reduced protein model (20), whose purpose is to
mimic the observed amyloid aggregation in solution with
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certain artiﬁcially designed amino-acid sequences. In this
article, we investigate the problem of prion propagation for
the transmembrane domain of CtmPrP, which infers a new
perspective of the pathological mechanism of prion diseases
as suggested by recent experiments (13–17). We speculate
that the amyloid aggregation in the membrane could lead to
rupture of membrane and cause the death of nerve cells. This
model is used to investigate the correlation between con-
centration and the average refolding time of a helical form
to a b-form, in the presence of a b-form template. We ﬁnd
that cooperativity plays an important role in the contact-
induced structure transformation. In this case, an excellent
agreement with experimental data for transgenic mice is
found in the calculated correlation between folding time and
prion concentration (25).
MODEL
In our model, the potential energy U of a membrane protein (MP) can be
expressed as U ¼ Umembrane 1 Uwater, where Umembrane and Uwater are the
potential energies of MPs in a membrane and in water, respectively (26). The
simulation box is divided into three regions including two water phases
separated by a hydrocarbon (membrane) phase of thickness L. For amino
acids within the membrane, their potential energy is given by Umembrane ¼
EH-bond1 Ebend, where EH-bond is the hydrogen-bonding energy and Ebend is
the bending energy of the chain. A hydrogen bond can form if two amino
acids are separated by four-lattice spacing (or 5.4 A˚). However, each amino
acid can, at most, participate in two hydrogen bonds. Moreover, hydrogen
bonding is highly directional and has a maximal strength when N-H and
O¼C bonds are co-linear. Therefore we model the hydrogen-bonding energy
by EH-bond ¼ +Æi,jæ j(ni  rij) (nj  rij)j dr(i,j),4, where ni is the N-H (or O¼C)
bond orientation of the ith amino acid, while r(i,j) and rij are the distance and
its unit vector between amino acids i and j. Since the backbone hydrogen
bonding is the dominant interaction for the formation of secondary structures
of MPs, its energy strength is set to unity. Furthermore we have explicitly
excluded the possibility of forming 27 ribbons and 310 helices due to steric
hindering by disallowing the hydrogen bonding between (i, i62) and
(i, i63) pairs. The bending energy of the chain is assumed to be e1 +i
(1cosui), where e1 is the bending rigidity and ui is the angle between two
consecutive bonds i and i11. For amino acids in water, their interactions are
modeled by a residue-residue contact potential (Econtact) and the hydro-
pathical interaction (Ehydropathy), i.e., Uwater ¼ Econtact 1 Ehydropathy. The
interactions between the exposed residues and the lipid bilayer are ignored.
Here we use the Thomas-Dill contact potential with strength e2 to model the
residue-residue interaction in water when residues are in contact (27). Since
MP residues exposed to water are mostly exterior residues, the positive
contact energies between exterior residues in this potential imply highly
dynamical loops of MPs in the water phase. The hydropathical interaction of
amino acids in water can be modeled by using a rescaled Hopp-Woods
hydropathy index [A, R, N, D, C, E, Q, G, H, I, L, K, M, F, P, S, T, W, Y, V]¼
[0.15,0.88,0.06,0.88, 0.29,0.06,0.88, 0, 0.15, 0.53, 0.53,0.88,
0.38, 0.74, 0, 0.09, 0.12, 1, 0.68, 0.44] with strength e3, which is mainly
determined by the Gibbs free energy change for transferring amino acids
from water into condensed vapor (28). In addition, the insertion of a poly-
peptide chain into a membrane will disturb the integrity of the membrane
and local lipid density around the chain, which increases the energy of the
membrane (29). We model this effect by introducing an effective lateral
pressure (P) applied to the polypeptide chain to minimize its lateral area A
(30). Therefore, to ﬁnd the ground state structure of MPs, the relevant
physical quantity to be minimized in our model is the enthalpyH¼ U1 PA.
In our simulations, the parameters of this model are chosen to be e1¼ 0.016,
e2 ¼ 0.3, e3 ¼ 0.66, P ¼ 0.59, and L ¼ 26, in which case the unique ground
state is a transmembrane helix for a single protein system but is a linear
hairpin aggregation for a multiprotein system. In this set of parameters, we
deliberately set the energy of a hairpin dimer to be only slighter lower than
that of two isolated helices. We have previously found that, for a protein
monomer, it is kinetically unfavorable to ﬁnd the state of a hairpin structure
due to the required nonlocal interaction (30). In fact, only ,4% of our
simulations will reach the hairpin state and the helical state is found in most
simulations. In the presence of a hairpin template, the kinetic barrier dis-
appears due to the interaction between protein monomer and the template.
It is easy to see the propagation of b-hairpins even with the current set of
parameters. If a different set of parameters is chosen, such as using a larger
value of e1, the aggregation of b-hairpins will be further stabilized and the
propagation of b-hairpins will be more prominent. In the absence of a
hairpin template, we have never seen the transition from two isolated helices
into a hairpin dimer.
Algorithm of simulations
Protein is represented as a chain of monomers in lattice space using the bond
ﬂuctuation model (31). Each monomer in the model is a cube of length
1 (lattice spacing) on a cubic lattice. The set of allowed bond vectors is B ¼
P(2,0,0)[P(2,1,0)[P(2,1,1)[P(2,2,1)[P(3,0,0)[P(3,1,0), where P(a,b,c)
stands for the set of all permutations and sign combinations of 6a, 6b,
6c. The number of conﬁgurations per bond is z ¼ 108. The length of one
bond can take any one of the ﬁve values: 2, 51/2, 61/2, 3, or 101/2 (in units of
lattice spacing). Chains satisfy the excluded volume constraint: no lattice site
may be occupied by more than one monomer. The set B is chosen to satisfy
the constraints of both excluded volume between monomers and topological
entanglement between chains (i.e., two chains cannot pass through each
other). If any other bond vectors were added to this set, some chains would
become ‘‘phantom’’ chains. The folding of a protein chain is simulated by
the Metropolis Monte Carlo (MC) algorithm in a cubic lattice at a constant
temperature T. At each instant, a residue is picked up at random and attempts
to move in any of the six directions by one lattice spacing. If any attempted
move of residues satisﬁes the excluded volume constraint and the new bond
vectors are still in the allowed set, then the move is accepted with probability
p ¼ min[1, exp(DH/T)], where DH is the enthalpy change of the system.
Each physical quantity calculated in the present work is averaged over 100
different runs.
FIGURE 1 The native a-helical conformation (a) and the metastable
b-hairpin conformation (b) of the amino-acid sequence HMAGAAAAGA
VVGGLGGYML GSAMV.
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RESULTS AND DISCUSSION
In Fig. 2, we display the average hydropathy index of a
S135V mutated Syrian hamster prion protein (SHaPrP29–231,
GG WNTGGSRYPG QGSPGGNRYP PQGGGTWGQP
HGGGWGQPHG GGWGQPHGGG WGQPHGGGWG
QGGGTHNQWN KPSKPKTNMK HMAGAAAAGA
VVGGLGGYML GSAMVRPMMH FGNDWEDRYY
RENMNRYPNQ VYYRPVDQYN NQNNFVHDCV
NITIKQHTVT TTTKGENFTE TDIKIMERVV EQMCTT-
QYQK ESQAYYDGRR S) for window sizes (WS) of 20,
24, and 25 residues. Our calculation on the average hy-
dropathy index for WS ¼ 20 ; 30 residues shows that
ShaPrP contains a stable TM domain stretching from H111 to
V135, which has the largest accumulated hydropathy index
(DE111135hydropathy ¼ 5:28) for various values of WS. Similar TM
domain (stretching from M112 to V135) is predicted if the
Hoop-Woods index is replaced by the Kyte-Doolittle index,
as shown in Fig. 3. In our model, the native conformation of
this TM domain corresponds to the structure of a simple
a-helical motif (Fig. 1 a), whereas the metastable structure
adopted a b-motif (Fig. 1 b). The conformational energies of
these structures are 13.9 and 8, respectively. With low-
temperature range (T ¼ 0.1–0.15) and the b-form as the
initial conﬁguration, the protein remains in the b-form for
simulations of 106 MC steps, conﬁrming its metastable
character. Fig. 4 shows the temperature dependence of
helical fraction and the mean ﬁrst passage time (MFPT) to
the helical state (ground state), starting from a random initial
conﬁguration. The optimal folding temperature for our model
is 0.31 (the corresponding thermal energy is;3 kJ/mol). The
average helical fraction of the chain is calculated during a
period of 103 MC steps for 10 different simulations at each
temperature, after the chain has been simulated for 105 MC
steps. The large values of helical fraction of the chain at
various temperatures imply that there is a large basin as-
sociated with the helical state in the conﬁguration space.
Then, a system of two interacting protein molecules has
been considered at T ¼ 0.31. One of the molecules has been
frozen in the b-form serving as a template. Such a frozen
template may happen in real systems for various reasons
(20,32). For example, this frozen template could be consid-
ered as a stable protein structure at the edge of a propagating
amyloid rod. The initial conﬁguration of the other protein is
the a-helical motif, which is free to diffuse in the membrane.
The a-helical form ﬁrst unfolds and then refolds to the
b-form in the presence of the template, assembling into a
larger b-type dimer structure (Fig. 5). Due to the favorable
intermolecule hydrogen bonding interaction, the energy of
FIGURE 2 Average hydropathy index of S135V mutated Syrian hamster
prion protein (SHaPrP29-231) for WS ¼ 20, 24, and 25 using the Hopp-
Woods hydropathy index. The predicted TM domain is also shown for these
three values of WS.
FIGURE 3 Average hydropathy index of S135V mutated Syrian hamster
prion protein (SHaPrP29–231) for WS ¼ 20, 24, and 25 using the Kite-
Doolittle hydropathy index. The predicted TM domain is also shown for
these three values of WS.
FIGURE 4 Temperature dependence of the chain’s helical fraction and
MFPT to the ground state for the amino-acid sequence HMAGAAAAGA
VVGGLGGYML GSAMV, starting from a random initial conﬁguration.
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the dimer (28) is lower than twice of the single-helical
molecule (27.8). If we use a random initial conﬁguration
for the second protein, it will quickly fold into the b-form
due to its contact with the template. Such a dimer structure is
stable for simulations longer than 106 MC steps at the
optimal folding temperature, in which case both proteins are
free to move. Nevertheless, the formation of the b-type
dimer has never been observed in our simulations (longer
than 107 MC steps) for systems starting from two unfolded or
helical structures, which implies that a spontaneous transi-
tion from the native to the propagating scrapie form of the
TM domain must be a rare event in our model. In this model,
the hairpin structure is kinetically unfavorable due to the fact
that hydrogen bonding is a local interaction for the helical
state but is a nonlocal interaction for the hairpin state. As
shown in Chen (30), only ,4% of simulations will ﬁnd a
(twisted) hairpin state before the chain folds into a helical
state, even when the (twisted) hairpin state is the ground
state. This kinetic barrier will prevent the chain from folding
into the hairpin structure in the absence of a hairpin template.
In the presence of a hairpin template, the kinetic barrier no
longer exists since proper contacts between monomer and
template can facilitate the formation of dimers.
Dimerization in the b-form could be considered as an
initiation event for a further propagation of an amyloid.
Although the deposition of amyloid ﬁbrils are often observed
in most prion diseases, recent experiments have suggested
that amyloid oligomers and protoﬁbrils may actually be the
toxic agents (33,34). We have also investigated the trimer-
ization process in which initially one molecule is frozen in
the b-form, and the other two freely moving molecules are
either both helical or one helical and one b-type. In all cases,
the resulting structure is a regular trimer composed of three
TM b-hairpins, as shown in Fig. 6.
The correlations between MFPT and the concentration (C)
of misfolded prions for dimerization (open squares) and
trimerization (open diamonds) are compared to the experi-
mental correlation curve between incubation time and in-
jected dose of Sc237 prions into transgenic mice (25), as
shown in Fig. 7. For the experimental curve, the injected dose
decreases with incubation time as a power law with an expo-
nent of 1.6. There seem to be two distinct phases for the
disease incubation after inoculation: a lag phase during which
there is little or no infectivity, and a doubling phase during
which the infectivity increases exponentially (35–37). Since
the lag phase period is much longer than the doubling phase
period and the time spent in the doubling phase does not
change appreciably with dose, here we approximate the in-
cubation time by the lag phase time. Note that in this article
we make no connection to the exponential growth of infec-
tivity during the incubation period, which is due to our
limited computing resources. In principle, as ﬁbrils accumu-
late, one might expect that an increased number of nucleation
sites would lead to an acceleration of infectivity with expo-
nential kinetics. Such an increase of nucleation sites could
result from a branching pattern of polymerization or from
fragmentation of aggregates. Breakage could occur if a
FIGURE 5 A model of prion disease propagation.
The native helical form of a prion misfolds to a
b-structure in the presence of the stiff misfolded
b-structure form.
FIGURE 6 Structures of model amyloid protoﬁbrils obtained in simula-
tions of three molecules.
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b-form within a ﬁbril makes a rare transition to the helix
form. Nevertheless, intensive computer simulations of the
exponential kinetics at our resolution are quite difﬁcult based
on our current computing facilities. A more coarse-grained
approach might be more appropriate to study this problem
(37). In the lag phase, our assumption is that each misfolded
prion protein nucleates to form a stable amyloid oligomer by
either dimerization or trimerization. The doubling phase
follows after amyloid oligomers grow to their ﬁssion
dimension. For our computer simulations of dimerization
and trimerization, we observe similar power law dependence
between the concentration of misfolded prions and MFPT.
However, their exponents are1.6 (0.9 for dimerization
and0.6 for trimerization). Such a discrepancy indicates that
these two processes are too slow to initiate prion disease at
low concentrations. It will take a much longer time for those
mice to develop signs of prion disease in these two processes.
Previous studies have suggested several sources of coop-
erative effect in the formation of b-hairpins. It has been found
that both hydrogen-bonding pattern and special side-chain
packing arrangement can provide cooperative stabilization of
strand-strand association in hairpin formation (38–40). It is
also observed that orientational order and lateral density
ﬂuctuations of the lipid matrix can enhance spontaneous
formation of hairpins for some membrane proteins (41,42).
Therefore we believe that the cooperative effect may play an
important role in the formation of prion oligomers. Computer
simulations of cooperativity-enhanced dimerization are per-
formed by biasing the preference in forming hydrogen-
bonding pairs of the TM domain. That is, if the motion of a
residue leads to the formation of a hydrogen-bonding pair
consistent with other hydrogen-bonding pairs in the template,
we add an extra favorable factor exp(bDh) in the moving
probability of this residue to enhance the cooperative hairpin
formation (without violating the detail balance), where Dh is
the change in the number of hydrogen-bonding pairs consis-
tent with hydrogen-bonding pairs in the template and b is the
cooperative factor (26). In other words, there is a bias in the
energy of hydrogen-bonding pairs depending on their orien-
tation. As shown in Fig. 8, it is found that the MFPT of
cooperative dimerization is minimized at b ¼ 0.001. Since
the cooperative effect is sequence-dependent, we assume that
the cooperative factor of the TM sequence discussed above is
at the optimal value. The cumulative distribution of ﬁrst
passage time of cooperative dimerization is shown in Fig. 9
for C ¼ 4.04% (dashed line) and 9.15% (solid line), which
shows a considerably broader cumulative distribution at low
concentrations as suggested in previous studies (37,43). It is
clear that the damage or death of neurons due to the aggre-
gation of transmembrane prions occur throughout the incu-
bation period. It is plausible to assume that transgenic mice
might enter the doubling phase and quickly develop clinical
signs of neurological dysfunction after cumulative death (or
cumulative aggregation of amyloid oligomers to their ﬁssion
dimension) of initially infected neurons reaches a critical
value (which we assume to be 50% of initially infected
neurons), since neuronal death could further enhance the
ﬁssion of the transmembrane amyloids. The relationship
between concentration and the time for 50% death rate is also
illustrated in Fig. 7. The correlation curves (solid circles for
MFPT and solid stars for time of 50% death rate) between
folding time and the concentration of misfolded PrP for this
cooperative dimerization are compared to the experimental
correlation curve in Fig. 7, showing an excellent agreement
between our simulations and the experiment. The scaling
exponent of the cooperative dimerization is 1.5 for the
curve of MFPT and is 1.6 for the curve of 50% death rate,
whose values are almost the same as the experimental scaling
exponent 1.6. Assuming a different critical value of death
rate (40% and 60%) only changes our results slightly. This
exponent is obtained from our model in a parameter-free
FIGURE 7 Comparison of the correlation curves between MFPT and the
concentration (C) of misfolded prions for dimerization (open squares),
trimerization (open diamonds), cooperative dimerization (solid circles,
MFPT; solid stars, 50% death rate), and experimental results from Prusiner
et al. (25).
FIGURE 8 The b-dependence of MFPT for a cooperative dimerization of
the amino-acid sequence HMAGAAAAGA VVGGLGGYML GSAMV.
The initial conﬁguration includes a b-hairpin template and a free a-helical
motif.
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manner. The energy parameters are chosen to insure that the
unique ground state is a transmembrane helix for a single
protein system but is a linear hairpin aggregation for a
multiprotein system. The degree of cooperativity is chosen to
be its optimal value. There is no free parameter to tune to ﬁt
the experimental exponent.
Note that we have assumed that the prion sequence con-
sidered in this study has an optimal cooperative factor to
facilitate the propagation of b-hairpins. If a different se-
quence is considered, its cooperative factor could deviate
from the optimal value and the formation of b-hairpins
would be considerably slowed down. Moreover, other
mutated sequences would have different thermodynamic
distribution of three topological forms of PrP, and only
overexpressing the transmembrane form CtmPrP has been
shown to be able to develop a spontaneous neurological
disease with scrapie-like features in some prion diseases such
as Gerstmann-Straussler-Scheinker disease. Thus although
the energy function of this model does not distinguish the
difference among various hydrophobic transmembrane se-
quences, the proposed propagation of b-hairpins in the
membrane would occur only when the sequence has an
optimal cooperative factor and its transmembrane CtmPrP
dominates the PrP distribution. Nevertheless, the complexity
to study sequence-dependent cooperative factor and ther-
modynamic distribution of various topological forms of PrP
would require detailed information of proteins at the atomic
level and beyond the scope of our coarse-grained model.
CONCLUSION
In conclusion, we have proposed in this article a possible
mechanism for prion diseases based on previous experimen-
tal ﬁndings. Our model assumes that aggregation of the
b-form TM domain of CtmPrP is responsible for the devel-
opment of these neurodegenerative diseases. We speculate
that the amyloid aggregation in the membrane could lead to
membrane rupture and cause the death of nerve cells. Based
on computer simulations, we have investigated the correla-
tion between folding time and the concentration of misfolded
PrP in various processes, including dimerization, trimeriza-
tion, and cooperative dimerization, and compared them with
the experimental correlation curve between incubation time
and injected dose of Sc237 prions. The exponent of exper-
imental curve is the same as that calculated from our model,
which has no free parameter to tune to ﬁt the experimental
value. We conclude that cooperativity-enhanced dimeriza-
tion may play an important role in the pathological mech-
anism of prion diseases.
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